A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast Cancer

NCT06471205 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

52

Enrollment

INDUSTRY

Sponsor class

Conditions

Triple-negative Breast Cancer

Interventions

DRUG: BL-B01D1
DRUG: PD-1 Monoclonal Antibody

Sponsor

Sichuan Baili Pharmaceutical Co., Ltd.

Collaborators

[object Object]